Quest Diagnostics Inc (DGX) Stake Lifted by Benjamin F. Edwards & Company Inc.

Share on StockTwits

Benjamin F. Edwards & Company Inc. lifted its holdings in Quest Diagnostics Inc (NYSE:DGX) by 32.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 544 shares of the medical research company’s stock after purchasing an additional 134 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Quest Diagnostics were worth $45,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in DGX. American Century Companies Inc. grew its stake in shares of Quest Diagnostics by 38.7% in the third quarter. American Century Companies Inc. now owns 4,109,526 shares of the medical research company’s stock worth $443,459,000 after purchasing an additional 1,147,470 shares in the last quarter. Marshall Wace LLP boosted its stake in Quest Diagnostics by 105.1% during the third quarter. Marshall Wace LLP now owns 1,525,559 shares of the medical research company’s stock valued at $164,623,000 after buying an additional 781,703 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Quest Diagnostics by 57.3% during the second quarter. Bank of New York Mellon Corp now owns 1,781,373 shares of the medical research company’s stock valued at $195,845,000 after buying an additional 648,706 shares in the last quarter. Macquarie Group Ltd. boosted its stake in Quest Diagnostics by 4.8% during the third quarter. Macquarie Group Ltd. now owns 6,708,232 shares of the medical research company’s stock valued at $723,882,000 after buying an additional 306,017 shares in the last quarter. Finally, Morgan Stanley boosted its stake in Quest Diagnostics by 95.5% during the third quarter. Morgan Stanley now owns 617,501 shares of the medical research company’s stock valued at $66,633,000 after buying an additional 301,621 shares in the last quarter. 87.19% of the stock is owned by institutional investors.

DGX has been the subject of several research reports. Canaccord Genuity reaffirmed a “buy” rating and set a $98.00 target price on shares of Quest Diagnostics in a research note on Friday, November 30th. Mizuho set a $108.00 target price on Quest Diagnostics and gave the company a “buy” rating in a research note on Tuesday, November 20th. Bank of America initiated coverage on Quest Diagnostics in a research note on Friday, October 19th. They set a “buy” rating for the company. Argus set a $106.00 target price on Quest Diagnostics and gave the company a “buy” rating in a research note on Wednesday, October 24th. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $121.00 target price on shares of Quest Diagnostics in a research note on Sunday, December 2nd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $104.56.

Shares of NYSE DGX opened at $89.88 on Thursday. Quest Diagnostics Inc has a 12 month low of $78.95 and a 12 month high of $116.49. The firm has a market cap of $12.21 billion, a PE ratio of 16.64, a P/E/G ratio of 1.83 and a beta of 0.89. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.15 and a quick ratio of 1.09.

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 30th. Stockholders of record on Tuesday, January 15th were issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.36%. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.50. The ex-dividend date was Monday, January 14th. Quest Diagnostics’s dividend payout ratio is currently 39.26%.

COPYRIGHT VIOLATION WARNING: “Quest Diagnostics Inc (DGX) Stake Lifted by Benjamin F. Edwards & Company Inc.” was originally published by BBNS and is owned by of BBNS. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://baseballnewssource.com/2019/02/14/quest-diagnostics-inc-dgx-stake-lifted-by-benjamin-f-edwards-company-inc/3214831.html.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.